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Abstract
Background: Accumulating evidences suggest that sex affects lung development. Indeed, a higher incidence of
respiratory distress syndrome is observed in male compared to female preterm neonates at comparable
developmental stage and experimental studies demonstrated an androgen-related delay in male lung maturation.
However, the precise mechanisms underlying these deleterious effects of androgens in lung maturation are only
partially understood.
Methods: To build up a better understanding of the effect of androgens on lung development, we analyzed by
microarrays the expression of genes showing a sexual difference and those modulated by androgens. Lungs of
murine fetuses resulting from a timely mating window of 1 hour were studied at gestational day 17 (GD17) and
GD18, corresponding to the period of surge of surfactant production. Using injections of the antiandrogen
flutamide to pregnant mice, we hunted for genes in fetal lungs which are transcriptionally modulated by
androgens.
Results: Results revealed that 1844 genes were expressed with a sexual difference at GD17 and 833 at GD18. Many
genes were significantly modulated by flutamide: 1597 at GD17 and 1775 at GD18. Datasets were analyzed by
using in silico tools for reconstruction of cellular pathways. Between GD17 and GD18, male lungs showed an
intensive transcriptional activity of proliferative pathways along with the onset of lung differentiation. Among the
genes showing a sex difference or an antiandrogen modulation of their expression, we specifically identified
androgen receptor interacting genes, surfactant related genes in particularly those involved in the pathway leading
to phospholipid synthesis, and several genes of lung development regulator pathways. Among these latter, some
genes related to Shh, FGF, TGF-beta, BMP, and Wnt signaling are modulated by sex and/or antiandrogen
treatment.
Conclusion: Our results show clearly that there is a real delay in lung maturation between male and female in this
period, the latter pursuing already lung maturation while the proper is not yet fully engaged in the differentiation
processes at GD17. In addition, this study provides a list of genes which are under the control of androgens within
the lung at the moment of surge of surfactant production in murine fetal lung.
Background
Accumulating evidence suggests that sex affects lung
development and physiology. Indeed, sex hormones
appear to exert regulatory effects on human lung devel-
opment and maturation during both fetal and neonatal
periods. During the fetal period, male lung maturation is
delayed compared with female and surfactant
production appears earlier in female than in male fetal
lungs [1]. In preterm infants, surfactant deficiency
greatly contributes to the development of respiratory
distress syndrome (RDS) [1] and its resulting morbidity
such as bronchopulmonary dysplasia (BPD), patent duc-
tus arteriosus, and long-term neurological disabilities
[2,3]. Consequently, male neonates have an increased
risk of developing RDS and a higher risk of morbidity
and mortality due to RDS compared with female neo-
nates [4]. Moreover, a higher incidence in male was also
observed for the development of new BPD, a pulmonary
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an anterior event [5].
Furthermore, substantial experimental data support a
role for sex hormones in lung development regulation.
Indeed, several genes have been shown to be expressed
with a sexual dimorphism within murine fetal maturing
lung [6]. More precisely, androgens have been shown to
exert inhibitory effects on lung maturation both in vitro
[7] and in vivo [8,9]. For instance, maternal treatment
with the androgen dihydrotestosterone (DHT) during
fetal rabbit development inhibits surfactant phospholi-
pids production in the female fetal lung, while maternal
treatment with the antiandrogen flutamide increases
surfactant phospholipids pr o d u c t i o ni nt h em a l ef e t a l
lung [9]. In human, androgens delay alveolar epithelial
type II (PTII) cell maturation in males compared with
females [10]. Similarly, androgens delay fetal lung sur-
factant production in a variety of species [11] by a
mechanism involving transforming growth factor-b
(TGF-b) signalling pathway [12].
To build up a better understanding of the biomolecu-
lar mechanisms underlying androgens effect on lung
development, we investigated the expression of genes
showing a sexual dimorphism and those modulated by
the presence of androgens at the moment of surge of
surfactant production in murine fetal lung. For achiev-
ing this goal, microarrays were performed on fetal
mouse lungs of both sexes harvested at gestational day
17 (GD17) and GD18 (term is GD19), preceded by
maternal daily injections of the pure antiandrogen fluta-
mide or the vehicule solution (control) from GD10. In
the mouse, GD17 and GD18 represent the transition
between canalicular and saccular stages of lung develop-
ment, which overlaps the surge of surfactant production.
Then, the present investigation has been designed to
provide valuable insights in the study of the signalling
mechanisms leading to surfactant synthesis and pulmon-
ary maturation. In general, the results show that thou-
sands of genes are transcriptionally modulated within
the developing lung in response to the fetal androgenic
status. More specifically, we report the modulation of
androgen receptor interacting genes, surfactant related
genes and particularly those involved in the pathway
leading to phospholipid synthesis, and several genes of
lung development regulator pathways.
Methods
Animals and housing
Protocols were approved by the Animal Care and Use
Committee and the Institutional Review Board of the
Centre de Recherche du Centre Hospitalier Universitaire
de Québec (protocol no. 2005-156). BALB/c mice (Mus
musculus) aged from 63 to 70 days and certified patho-
gen free were purchased from Charles River
Laboratories (St-Constant, QC, Canada). These were
housed in a room maintained at 22 +/- 3°C, 50 +/- 20%
relative humidity and on a 12-hours cycle (07:15-19:15
hours) of fluorescent lighting (300 Lux). Commercial
diet (Global 18% Protein Rodent Diet, Teklad, Montréal,
QC, Canada) and tap water were provided ad libitum.
New animals were acclimatized to these conditions for 7
to 14 days prior to be timely mated in a one hour mat-
ing window as previously described [13].
Experimental procedures
Flutamide antiandrogen (kindly provided by Dr Fernand
Labrie) was dissolved in a saline vehicule solution (0.9%
NaCl) containing 1% gelatin (W/V) (ACP Chemicals,
Saint-Léonard, QC, Canada) and 10% dimethylsulfoxide
(DMSO) (Sigma, St. Louis, MO). Pregnant females
received a daily sub-cutaneous injection of 200 μl of flu-
tamide (1 mg) or vehicule solution from GD10 to the
day prior to harvesting day. Pregnant females were sacri-
ficed by exposure to CO2 at GD17 or GD18. From each
fetus, lungs and a rear leg were harvested and rapidly
frozen on dry ice and then stored at -80°C until use.
Fetal sex determination
Fetal sex was identified by examination of the genital
tract with a dissecting microscope at 15× magnification
and confirmed by PCR amplification of the male-specific
Sry gene [14] (GenBank: X67204) from fetal rear leg.
DNA was purified by phenol-chloroform extraction fol-
lowed by ethanol precipitation. A hot start procedure
with Taq DNA Polymerase kit (Roche Diagnostics,
Laval, QC, Canada) was achieved and PCR reactions
were performed according to the protocol of the manu-
facturer with 0.04 nM of each Sry primer (forward:
nucleotide position 36-55, 5’-TATGGTGTGGTCCC
GTGGTG-3’; reverse: nucleotide position 337-317, 5’-
ATGTGATGGCATGTGGGTTCC-3’), resulting in a
282 nucleotides amplicon. The following PCR conditions
w e r eu s e d :9 4 ° Cf o r5m i n .a n d7 2 ° Cf o r1 0m i n .f o l -
lowed by 34 cycles of 94°C for 1 min., 65°C for 1 min.
and 72°C for 1 min. Final extension was done at 72°C
for 10 min. Agarose gel electrophoresis was used for
amplicon visualization.
RNA extraction and sampling
Total RNA was extracted from fetal lung using Tri-
reagent, a mixture of phenol and guanidine thiocyanate
in a monophasic solution (Molecular Research Center,
Cincinnati, OH) as described previously [15]. Each RNA
sample was purified on a CsCl gradient as described
[16], using a TLA 120.2 rotor in an Optima MAX cen-
trifuge (Beckman, Mississauga, ON, Canada). The qual-
ity of RNA was monitored by micro-capillary
electrophoresis (Bioanalyser 2100, Agilent Technologies,
Mississauga, ON, Canada).R N As a m p l e sf r o mt h r e e
fetuses of the same sex but from distinct litters were
then pooled (n = 1). Each experimental group was
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in 18 RNA pools for microarray hybridization, were the
following: vehicule-injected males harvested at GD17
(17 m) or GD18 (18 m), vehicule-injected females har-
vested at GD17 (17 f) or GD18 (18 f), and flutamide-
t r e a t e dm a l e sh a r v e s t e da tG D 1 7( 1 7f l u t )o rG D 1 8( 1 8
flut).
Preparation of probes
For each RNA pool, 20 μg of total RNA was converted
to cDNA by using SuperScript II reverse transcriptase
(Invitrogen), and T7-oligo-d(T)24 (Geneset) as a pri-
mer. T7 BioArray High Yield RNA Transcript Labeling
Kit was used to produce biotinylated cRNA. The mix-
ture (20 μl final volume) was incubated at 37°C for 5 h
with gentle mixing every 30 min. Labelled cRNA was
purified using a RNeasy Mini Kit (Qiagen) according
to the protocol of the manufacturer. Purified cRNA
was fragmented into segments of 20-300 nucleotide
length by incubation in a fragmentation buffer (100
mM potassium acetate, 30 mM magnesium acetate, 40
mM Tris-acetate pH 8.1) for 20 min at 94°C. The qual-
ity of cRNA amplification and cRNA fragmentation
was monitored by micro-capillary electrophoresis
(Bioanalyser 2100, Agilent Technologies, Mississauga,
ON, Canada).
Microarray hybridization, scanning, and analysis
Fifteen micrograms of fragmented cRNA was hybridized
for 16 h at 45°C with constant rotation, using a mouse
oligonucleotide array MOE430 2.0 (Genechip, Affyme-
trix, Santa Clara, CA). After hybridization, chips were
processed by using the Affymetrix GeneChip Fluidic
Station 450 (protocol EukGE-WS2v5_450). Staining was
made with streptavidin-conjugated phycoerythrin (SAPE;
Molecular Probes), followed by amplification with a bio-
tinylated anti-streptavidin antibody (Vector Labora-
tories), and by a second round of SAPE. Chips were
scanned using a GeneChip Scanner 3000 G7 (Affyme-
trix) enabled for High-Resolution Scanning. Images were
extracted with the GeneChip Operating Software (Affy-
metrix GCOS v1.4). Quality control of microarray chips
was performed using the AffyQCReport software [17]. A
comparable quality between microarrays was demanded
for all microarrays within each experiment.
The MOE430 2.0 microarray provides coverage of
over 45,000 probe sets corresponding to about 39,000
transcripts and variants. The probe sets were selected
from sequences derived from GenBank, dbEST and
RefSeq. The sequence clusters were created from the
UniGene database (Build 107, June 2002) and then
refined by analysis and comparison with the publicly
available draft assembly of the mouse genome from the
Whitehead Institute Center for Genome Research
(MSCG, April 2002). Data sets have been deposited in
GEO (GSE18135).
Statistical analysis
The background subtraction and normalization of probe
set intensities was performed using the Robust Multiar-
ray Analysis (RMA) method described by Irizarry et al.
[ 1 8 ] .T oi d e n t i f yd i f f e r e n t i a l l ye x p r e s s e dg e n e s ,g e n e
expression intensities were compared using a moderated
t-test and a Bayes smoothing approach developed for a
low number of replicates [19]. To correct for the effect
of multiple testing, the false discovery rate was esti-
mated from p values derived from the moderated t-test
statistics [20]. The analysis was performed using the
affylmGUI Graphical User Interface for the limma
microarray package [21].
Results
Fetal lung gene expression was compared at both GD17
and GD18 between males and females (17 f vs.1 7m
and 18 f vs. 18 m) and between males and flutamide-
treated males (17 m vs.1 7f l u ta n d1 8mvs.1 8f l u t )
(Fig. 1). Analysis indicates that more than twice of the
genes were expressed with a sexual difference at GD17
than at GD18 (1844 vs. 833) while flutamide modulated
the expression level of a comparable number of genes at
GD17 and GD18 (1597 and 1775, respectively). There
was a substantial overlap between the genes expressed
with sexual dimorphism and those affected by flutamide
(590 at GD17 and 428 at GD18). In addition, 306 genes
showed sexual difference at both GD17 and GD18 and
321 genes were modulated by flutamide at both studied
gestational ages. Finally, 54 genes showed expression
modulation in all the four comparison protocols. In
order to assess the validity of the microarrays, we
achieved real-time quantitative PCR for a few genes ran-
domly selected among those presenting sexual difference
and/or flutamide sensitivity by using cDNA from the
same experimental groups than those used for microar-
ray experiments. The genes considered for quantitative
PCR were cyclin-dependant kinase 6 (Cdk6), nuclear
factor I/B (Nfib), pre B-cell leukemia transcription factor
1 (Pbx1), phosphatase and tensin homolog (Pten), sir-
tuin 1 (Sirt1), and nuclear receptor subfamily 2, group
C, member 2 (Nr2c2). In each case, the trend observed
by quantitative PCR confirmed the trend observed in
microarray results (Fig. 2).
At GD17, 88% of the genes expressed with a sexual
difference were more highly expressed in male lungs
than in female lungs and this proportion decreased to
59% at GD18 (Fig. 3). Among the 1597 genes signifi-
cantly modulated at transcriptional level by flutamide at
GD17, 36% were up-regulated and 64% were down-
regulated. This tendency is amplified at GD18 where
only 19% of the modulated genes were transcriptionally
up-regulated by flutamide while 81% were down-
regulated.
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antiandrogen treatment were analyzed by using the
Gene Ontology website http://www.geneontology.org in
order to delineate to which biological processes and/or
molecular functions they are associated. In accordance
with the scope of this study, focus was placed on genes
related to surfactant production and regulation, pulmon-
ary development and physiology, lipid processing, and
androgen receptor (AR) signalling (Fig. 4). Surprisingly,
a relatively low number of genes related to these pro-
cesses showed sexual difference and/or flutamide sensi-
tivity, except for cellular lipid metabolic process. Indeed,
23 and 12 genes related to this biological process were
expressed with a sex difference at GD17 and GD18,
respectively, and 29 and 27 genes were affected by fluta-
mide treatment at these gestational ages.
The subset of genes presenting sex difference and
being affected by flutamide at the same gestational age
(590 at GD17, 428 at GD18) were regrouped in accor-
dance with their pattern of relative pulmonary expres-
sion level among experimental groups (Table 1). For the
majority of those genes, the expression level was higher
in males than in females (571 at GD17 and 344 at
GD18; summation of genes with expression patterns #2
and #5). However, at GD18 the proportion of genes
highly expressed in females represents about 20% (84
genes; expression patterns #3 and #4) of the total genes
whereas at GD17 it counts for only 3% (19 genes;
expression patterns #3 and #4). Some of those genes are
related to lipid processing, hormones, and lung function.
Since they represent potential important players in the
action of androgens in fetal lung development, they are
specifically presented in Table 2.
In addition to the genes presenting both sex- and flu-
tamide-driven modulations, some others presented
either a sex difference or a transcriptional modulation
by flutamide treatment at GD17 or GD18. Many of
these genes are related to androgen receptor signalling
and are more specifically known as co-regulators in the
formation of AR complex (Fig. 5). Among these genes,
an important proportion was modulated at GD17, the
majority of them being more highly expressed in males
Figure 1 Overview of microarray results obtained from fetal
mouse lungs. Gene expression levels were compared at both
GD17 and GD18 in males versus females (17 f vs. 17 m and 18 f vs.
18 m) as well as in males versus flutamide-treated males (17 m vs.
17 flut and 18 m vs. 18 flut). The number of genes differentially
expressed for each comparison appears in grey boxes. White boxes
contain the number of differentially expressed genes shared by
comparisons to which they are connected. Flut: flutamide treated
males, m: males, f: females.
Figure 2 Microarray validation by quantitative real-time PCR (Q-PCR). Q-PCR were achieved for six genes randomly selected among those
for which microarrays reveal a sexual difference and/or flutamide sensitivity: cyclin-dependant kinase 6 (Cdk6), nuclear factor I/B (Nfib), pre B-cell
leukemia transcription factor 1 (Pbx1), phosphatase and tensin homolog (Pten), sirtuin 1 (Sirt1), and nuclear receptor subfamily 2, group C,
member 2 (Nr2c2). Gene expression data are shown as a relative fold-change of the second experimental group over the first experimental
group in each comparison. Genes showing increased expression in male (m) compared to female (f) or in male (m) compared to flutamide
treated male (flut) are placed above the axis and those with decreased expression below the axis.
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males (Fig. 5B). Conversel y ,o n l y5g e n e sw e r em o r e
highly expressed in females than in males (2 at GD17
and 3 at GD18) and only 3 genes were up-regulated
within the fetal male lung by flutamide treatment (2 at
GD17 and 1 at GD18).
Several other genes presenting either a sex difference
or transcriptional modulation by flutamide treatment at
GD17 or GD18 are known to be involved in pulmonary
development signalling pathways or in surfactant synth-
esis or regulation (Table 3). Indeed, our results show
that some components of signalling pathways mediating
lung development and/or maturation present a transient
sex difference in expression, being more highly
expressed in males at GD17 but not at GD18. Genes
related to surfactant synthesis and regulation also
Figure 3 Modulation of fetal pulmonary gene expression by sex and antiandrogen treatment. Grey boxes contain the number of genes
highly expressed in male fetal lungs harvested at GD17 or GD18 (17 m and 18 m) when compared with timely corresponding female fetal
lungs (17 f and 18 f) or flutamide-treated male fetal lungs (17 flut and 18 flut). Numbers within white boxes represent the number of genes for
which the expression is lower in male fetal lungs than in the compared group. Flut: flutamide treated males, m: males, f: females.
Figure 4 Profile of biological processes and molecular functions of genes transcriptionally modulated by sex and antiandrogen
treatment. Modulated genes were analyzed on Gene Ontology website www.geneontology.org and results were reported for genes included
within categories (GO:category number) related to surfactant production and regulation, pulmonary development and physiology, lipid
processing, and androgen receptor signalling. Flut: flutamide treated males, m: males, f: females.
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tant at GD17 that at GD18. More specifically, this sex
regulation at GD17 favors high expression level for
f e m a l e sf o rg e n e si n v o l v e di ns p h i n g o l i p i ds y n t h e s i s
while genes involved in phosphatidyl choline synthesis
or in IGF signalling tend to be more highly expressed in
male than in female lungs. Among the surfactant-related
genes, surfactant associated proteins A, B, and C were
transcriptionally up-regulated by flutamide treatment at
GD17, reaching a level comparable to the one of female
lungs at GD18.
Discussion
We previously achieved a microarray analysis of the sex
difference in fetal mouse lungs at GD15.5, GD16.5, and
GD17.5 by using overnight mating [6]. This protocol
revealed only 83 genes presenting a sex difference at
one or more of the studied time points. The much more
larger number of genes showing a sex difference we
report here could be explained by the mating window
which was reduced to 1 h for the current study. The
mouse gestational period is very short (term GD19).
Therefore, because the sex difference results from a
delay in modulation, the gestation period corresponding
to this delay should be very short. As a consequence,
overnight mating window previously used may have
restrained the amount of genes showing a sex difference.
Moreover, in the current study, we also performed
microarray analysis of male fetal lungs following fluta-
mide or vehicle (negative control) administration in
order to identify genes in the male fetal lung that were
directly or indirectly under the control of androgens.
Androgen receptor interacting genes
The AR, which mediates androgen effects, is a nuclear
transcription factor that binds to androgen-responsive
elements as well as to co-activators and general tran-
scription factors to control transcription of androgen-
regulated genes [22]. As a ligand-dependent transcrip-
tion factor, the AR is activated by binding to one andro-
gen molecule: testosterone or DHT. AR is present in
both male and female lungs [23]. Moreover, in the
developing lung, there is active androgen metabolism
where androgen synthesis and inactivation take place
[23,24] making the lung a candidate organ for direct
androgen control. The lack of a functional AR in tissues
of the testicular feminized mice (Tfm) is well-documen-
ted and no difference was observed in the phosphatidyl
choline/sphingomyelin ratio between Tfm males and
normal females [8]. In Tfm males, this ratio was not
altered by exogenous androgen while it is lowered in the
female. This finding strongly indicates that androgen
acts to alter fetal lung development via the AR. The for-
mation of AR transcriptional complex requires its func-
tional and structural interaction with several co-
regulators [25]. Our results show that, during the period
overlapping the surge of surfactant synthesis, there is an
obvious difference in AR signalling regulation between
male and female lungs. Indeed, the higher androgen
concentration occurring in male lungs is accompanied
by a notably higher expression level of many co-factors/
co-regulators of AR. Moreover, many of them are
androgen-regulated, as testify their flutamide-sensitive
expression. One of those cofactors, Pten, is particularly
interesting while it is able to regulate AR signalling in
both direct and indirect manner. Pten interacts directly
with AR to suppress androgen-induced AR nuclear
translocation and it also regulates AR activity via a
PI3K/Akt-dependent pathway [26]. In Drosophila, PTEN
was demonstrated to suppress cell growth and G1/S
progression by down-regulating the PI3K/Akt pathway
and to inhibit the G2/M transition through an alterna-
tive mechanism, perhaps involving regulation of the
cytoarchitecture [27]. Thus, Pten appears to be an
important regulator in the timing of cell proliferation
and maturation.
Lung development regulators
During embryonic and pseudoglandular stages of lung
development, sonic hedgehog (Shh) plays an important
positive role. Indeed, lack of Shh signalling leads to
severe pulmonary hypoplasia [28]. The output of hedge-
hog signalling is mediated by the modulation of the Gli
Table 1 Expression patterns of genes transcriptionally modulated by sex and antiandrogen treatment within fetal
lung
Expression pattern Relative expression level among
groups
1
Number of genes
GD17
2 GD18
#1 flut > m > f 0 0
#2 m > flut > f 359 93
#3 flut > f > m 7 21
#4 f > flut > m 12 63
#5 m > f > flut 212 251
#6 f > m > flut 0 0
1Groups are flutamide treated males (flut), males (m), and females (f)
2GD = Gestational day
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treatment
Biological function Gene symbol Gene name Expression pattern
1
GESTATIONAL DAY 17
Steroid Hsd17b12 Hydroxysteroid (17-beta)
dehydrogenase 12
#2 (m > flut > f)
Androgen Ext1 Exostoses (multiple) 1 #2 (m > flut > f)
Glucocorticoid Glcci1 Glucocorticoid induced transcript 1 #5 (m > f > flut)
Lipid binding Prkca Protein kinase c, alpha #5 (m > f > flut)
Lipid binding Ncam1 Neural cell adhesion molecule 1 #5 (m > f > flut)
Lipid binding Gpc6 Glypican 6 #2 (m > flut > f)
Steroid hormone receptor activity Nr6a1 Nuclear receptor subfamily 6, group
a, member 1
#2 (m > flut > f)
Steroid hormone receptor activity Nr2c2 Nuclear receptor subfamily 2, group
c, member 2
#2 (m > flut > f)
Cellular lipid metabolic process Sgpp1 Sphingosine-1-phosphate
phosphatase 1
#2 (m > flut > f)
Cellular lipid metabolic process Pbx1 Pre b-cell leukemia transcription
factor 1
#5 (m > f > flut)
Cellular lipid metabolic process Hsd17b12 Hydroxysteroid (17-beta)
dehydrogenase 12
#2 (m > flut > f)
Cellular lipid metabolic process Hadhb Hydroxyacyl-coenzyme A
dehydrogenase/3-ketoacyl-
coenzyme A thiolase/enoyl-
coenzyme A hydratase (trifunctional
protein), beta subunit
#2 (m > flut > f)
Cellular lipid metabolic process Ggtla1 Gamma-glutamyltransferase-like
activity 1
#3 (flut > f > m)
Respiratory gaseous exchange Pbx3 Pre b-cell leukemia transcription
factor 3
#2 (m > flut > f)
Respiratory tube development Nfib Nuclear factor i/b #2 (m > flut > f)
Respiratory tube development Foxp1 Forkhead box P1 #5 (m > f > flut)
Embryonic development Kif1b Kinesin family member 1b #2 (m > flut > f)
Embryonic development Ext1 Exostoses (multiple) 1 #2 (m > flut > f)
GESTATIONAL DAY 18
Lipid binding Rock1 Rho-associated coiled-coil forming
kinase 1
#5 (m > f > flut)
Lipid binding Nr5a2 Nuclear receptor subfamily 5, group
a, member 2
#5 (m > f > flut)
Steroid hormone receptor activity Nr5a2 Nuclear receptor subfamily 5, group
a, member 2
#5 (m > f > flut)
Cellular lipid metabolic process Pip5k3 Phosphatidylinositol-3-phosphate/
phosphatidylinositol 5-kinase, type III
#4 (f > flut > m)
Cellular lipid metabolic process Pbx1 Pre b-cell leukemia transcription
factor 1
#4 (f > flut > m)
Cellular lipid metabolic process Nr5a2 Nuclear receptor subfamily 5, group
a, member 2
#5 (m > f > flut)
Cellular lipid metabolic process Idi1 Isopentenyl-diphosphate delta
isomerase
#2 (m > flut > f)
Cellular lipid metabolic process Elovl6 Elovl family member 6, elongation
of long chain fatty acids (yeast)
#2 (m > flut > f)
Cellular lipid metabolic process Dhcr24 24-dehydrocholesterol reductase #2 (m > flut > f)
Cellular lipid metabolic process Crls1 Cardiolipin synthase 1 #5 (m > f > flut)
Lipid transport Osbpl9 Oxysterol binding protein-like 9 #4 (f > flut > m)
Respiratory gaseous exchange Fut8 Fucosyltransferase 8 #4 (f > flut > m)
Respiratory tube development Gli1 Gli-kruppel family member gli1 #2 (m > flut > f)
1Genes are situated among their corresponding expression patterns presented in Table 1. Flut: flutamide treated males. m: males. f: females.
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Page 7 of 14Figure 5 Genes associated to androgen receptor signalling that are modulated by sex or antiandrogen treatment. Genes for which the
pulmonary expression level is modulated by sex (A) or antiandrogen treatment (B) at GD17 or GD18. The color gradient within boxes represents
the relative magnitude in the differential expression level between compared groups; darker is the box, greater is the difference. Flut: flutamide
treated males, m: males, f: females.
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treatment
Process
1 Symbol Gene name Modulation
2
LUNG DEVELOPMENT REGULATORS
Shh signaling Gli1 GLI-Kruppel family member GLI1 17 m >17 f; 18 m >18 f
Shh signaling Gli3 GLI-Kruppel family member GLI3 17 m >17 f; 18 m >18 f
FGF signaling Fgf10 Fibroblast growth factor 10 17 m >17 f
TGF-b Signaling Tgfbr3 Transforming growth factor, beta re
ceptor III
17 m >17 f
TGF-b Signaling Tsc22d1 TSC22 domain family, member 1 17 m >17 f
TGF-b Signaling Tgfb2 Transforming growth factor, beta 2 17 flut >17 m
BMP signaling Bmpr2 Bone morphogenic protein receptor,
type II
17 m >17 f; 18 m >18 flut
BMP signaling Gdf10 Growth differentiation factor 10 17 m >17 flut
BMP signaling Gdf15 Growth differentiation factor 15 17 flut >17 m
Wnt signaling Gsk3b Glycogen synthase kinase 3 beta 17 m >17 f
Wnt signaling Ctnna1 Catenin (cadherin associated
protein), alpha 1
17 m >17 f
Wnt signaling Tcf4 Transcription factor 4 17 m >17 f
Wnt signaling Crebbp CREB binding protein 17 m >17 f
SURFACTANT RELATED GENES
Phosphatidyl cholin synthesis Lpin2 Lipin 2 17 m >17 f; 18 m >18 f
Phosphatidyl cholin synthesis Chka Choline kinase alpha 17 m >17 f; 17 m >17 flut; 18 m
>18 f; 18 m >18 flut
Phosphatidyl cholin synthesis Cds2 CDP-diacylglycerol synthase
(phosphatidate cytidylyltransferase)
2
18 flut >18 m
Phosphatidyl cholin synthesis Aytl2 (Lpcat1) Lysophosphatidylcholine
acyltransferase 1
17 flut >17 m
Sphingolipids synthesis Mgll Monoglyceride lipase 17 f >17 m
Sphingolipids synthesis Aldh9a1 Aldehyde dehydrogenase 9,
subfamily A1
17 f >17 m
Sphingolipids synthesis Pnliprp2 Pancreatic lipase-related protein 2 17 f >17 m
Sphingolipids synthesis Sgpp1 Sphingosine-1-phosphate
phosphatase 1
17 f >17 m
Sphingolipids synthesis Dusp11 Dual specificity phosphatase 11
(RNA/RNP complex 1-interacting)
17 f >17 m
Sphingolipids synthesis Crls1 Cardiolipin synthase 1 17 f >17 m; 18 m >18 f
Sphingolipids synthesis Gba Glucosidase, beta, acid 17 f >17 m
Surfactant proteins Sftpa1 Surfactant associated protein A1 17 flut >17 m; 17 flut >17 f; 18 m
>17 m; 18 f >17 f
Surfactant proteins Sftpb Surfactant associated protein B 17 flut >17 f; 18 m >17 m; 18 f >17
f
Surfactant proteins Sftpc Surfactant associated protein C 17 flut >17 f; 18 m >17 m; 18 f >17
f; 18 m >18 flut
Surfactant proteins Sftpd Surfactant associated protein D 18 m >17 m; 18 f >17 f
SURFACTANT REGULATION
Miscellaneous regulators Klf5 Kruppel-like factor 5 17 flut >17 m; 17 flut >17 f
Miscellaneous regulators Ltbp1 Latent transforming growth factor
beta binding protein 1
17 m >17 f
Miscellaneous regulators Pten Phosphatase and tensin homolog 17 m >17 f; 17 m >17 flut
Miscellaneous regulators Magi1 Membrane associated guanylate
kinase, WW and PDZ domain
containing 1
17 m >17 f
Miscellaneous regulators Ptges2 Prostaglandin E synthase 2 17 f >17 m
IGF signaling Igfbp2 Insulin-like growth factor binding
protein 2
17 m >17 flut
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malian Gli gene family consists of three members, Gli1,
Gli2, and Gli3 [29], which are expressed in the lung
mesenchyme during the pseudoglandular stage of devel-
opment [30]. While Gli1 and Gli2 are transcriptional
activators of Shh signalling, Gli3 is a bipotential tran-
scription factor, and the repressor form of Gli3, gener-
ated as a result of proteolytic cleavage, is activated in the
absence of Shh signalling [31]. As a consequence, we do
not know whether the higher expression of Gli3 observed
for males in our study tend to increase Shh activation. In
contrast, the fact that Gli1expression is also higher in
males clearly suggests that Shh signalling should be
higher in male than in female developing lungs.
Some of the signalling components of pulmonary
epithelial-mesenchymal interaction, essential for branch-
ing morphogenesis, are also more expressed in male than
in female lungs, such as Fgf10 and Bmpr2 genes. Mem-
bers of the fibroblast growth factor (FGF) family and in
particular Fgf10 are potent chemotactic signalling mole-
cules. Fgf10 elicits lung budding and branching morpho-
genesis [32]. Disruption of Fgf10 results in a complete
lack of lung parenchyma distal to the trachea [33] and, in
vitro, Fgf10 alone is both necessary and sufficient for
morphogenesis in mesenchyme-free endodermal explants
[32]. Fgf10 shows a sex-dependent expression at GD17
with higher levels in males, suggesting that the FGF10-
dependent growth is still continuing in the male lung at
this time of gestation. In contrast to FGFs, the role of
TGF-b is thought to be inhibitory for embryonic lung
branching morphogenesis. Tgfbr3, a TGF-b receptor par-
ticipating in TGF-b-mediated negative regulation of lung
organogenesis [34], is strongly expressed in male lung at
GD17. Another TGF-b-dependent protein involved in
differentiation process is Tsc-22. This protein enhances
TGF-b-dependent erythroid cell differentiation [35] and
modulates Smad activity, which may influence cell differ-
entiation in many different tissues, including the lung.
Like Tgfbr3, Tsc-22 is more highly expressed in male
lungs on GD17. One of TGF-b isoforms, TGF-b2 (coded
by mouse Tgfb2 gene) is transcriptionally induced by flu-
tamide treatment at GD17. Lungs of the Tgfb2 null mice
revealed no gross morphological defects prenatally, but
display collapsed conducting airways postnatally [36], so
Tgfb2 seems to be essential for the development and
maintenance of the respiratory function.
Contrary to Fgf10 and Gli which are expressed in the
mesenchyme, Bmp proteins (bone morphogenetic pro-
teins) are expressed in the adjacent pulmonary epithe-
lium. Bmps constitute the largest group of cytokines
belonging to the TGF-b superfamily. Originally, they
were identified as molecules regulating growth and dif-
ferentiation of bone and cartilage. However, they also
control growth, differentiation, and apoptosis in a
diverse number of cell lines, including mesenchymal and
epithelial cells, regulating embryogenesis and contribut-
ing to the maintenance and repair of adult tissues [37].
Bmp proteins signal through two subtypes of receptors:
Bmpr1 and Bmpr2. Bmpr2 is distinguished from other
TGF-b superfamily members in that it initiates intracel-
lular signalling in response to the specific ligands Bmp-
2, Bmp-4, Bmp-6, Bmp-7, growth and differentiation
factor 5 (Gdf-5), and Gdf-6 [38]. We report that Bmpr2
gene is highly expressed in male lungs compared to
female lungs at GD17, and compared to flutamide-trea-
ted males at GD18. None of the mentioned Bmp or Gdf
ligands is regulated according to sex, but Gdf10 and
Gdf15 show androgen-responsive expression, being
respectively down- and up-regulated by flutamide treat-
ment at GD17. Gdf15 is an important determinant of
collecting duct lengthening in mouse, and evidences
suggest that it is also involved in development [39]. It
was also shown to be regulated during keratinocyte dif-
ferentiation [40] while Gdf15 mRNA and protein
expression patterns correlate with proliferative activity
and cellular differentiation during the various stages of
normal prostate development [41]. Gdf10 was localized
to areas of programmed cell death in the limb where it
mediates retinoic receptor signalling [42]. This gene has
also putative tumor suppressor functions, being hyper-
methylated and down-regulated in lung cancers [43].
Therefore, these two Gdf genes seem to be involved in
the promotion (Gdf15) or the inhibition (Gdf10) of pro-
liferation and differentiation in fetal lung development.
Table 3: Genes associated with pulmonary development or surfactant that are modulated by sex and/or antiandrogen treatment
(Continued)
IGF signaling Igfbp5 Insulin-like growth factor binding
protein 5
17 m >17 flut
IGF signaling Igf1 Insulin-like growth factor 1 17 m >17 flut
IGF signaling Igfr2 (Fcgr2b) Fc receptor, IgG, low affinity IIb 17 m >17 flut
1Shh: sonic hedgehog, FGF: fibroblast growth factor, TGF-b: transforming growth factor beta, BMP: bone morphogenetic protein, Wnt: wingless integration site,
PC: phosphatidyl choline, IGF: insulin growth factor.
2Flut: flutamide treated males, m: males, f: females.
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tions in many embryonic tissues belong to the Wnt
(wingless-related) family. Wnts signal through multiple
pathways, the most well-characterized being the canoni-
cal b-catenin/TCF pathway [44]. In this pathway,
secreted Wnt proteins bind to Frizzled receptors on cell
membranes, activating Disheveled protein, which in turn
inactivates Gsk3. Giving that Gsk3 phosphorylates b-
catenin leading to the subsequent degradation of this
molecule, its inactivation inhibits phosphorylation of b-
catenin. Hypophosphorylation stabilizes b-catenin,
which is then transported to the nucleus where it het-
erodimerizes with members of the TCF family of tran-
scription factors and Creb binding protein (Crebbp) to
activate downstream target genes. b-catenin, a central
molecule of canonical Wnt signalling, has been shown
to localize in the undifferentiated primordial epithelium,
differentiating alveolar epithelium, and adjacent
mesenchyme [45]. In mouse, b-catenin dependent sig-
nalling is essential to the formation of the peripheral air-
w a y so ft h el u n g s .A c c o r d i n gt oo u rr e s u l t s ,g e n e s
encoding for Gsk3, b-catenin, Tcf4, and Crebbp are all
more highly expressed in male at GD17, suggesting
involvement of these genes in some differentiating pro-
cesses presenting a temporal delay for one sex.
Surfactant related genes
Five decades ago, it was already suggested that surfac-
tant deficiency could cause hyaline membrane disease,
currently called RDS. This disease of prematurely born
infants is due to a lack of surfactant [46]. The surfactant
complex is composed by lipids (90%) and proteins (10%)
[47]. Among the surfactant lipids, the most abundant
(70%) is phosphatidylcholine (PC), principally as dipal-
mitoylphosphatidylcholine (DPPC). Among the enzymes
involved in PC synthesis, we report that lipin 2 (Lpin2)
and choline kinase a (Chka) are more highly expressed
in male than female lungs. In addition, Chka is more
highly expressed in male than in flutamide-treated male.
The Cds2 gene encoding for the enzyme responsible for
CDP-diacylglycerol synthesis does not show a sex differ-
ence in expression, while it is up-regulated by flutamide
at GD18. The main gene responsible for DPPC synth-
esis, Aytl2, is up-regulated by flutamide at GD17. Thus,
the main pathway leading to PC and DPPC synthesis
seems to be regulated by an androgen-sensitive mechan-
ism. A pathway susceptible to be more active in female
than in male lungs on GD17 is sphingolipids synthesis
for which genes Mgll, Aldh9a1, Pnliprp2, Sgpp1,
Dusp11, Crls1, and Gba are all more strongly expressed
in female than in male lungs.
The surfactant proteins play crucial roles in the struc-
ture, function, and metabolism of surfactant. Four pro-
teins enter in the composition of surfactant: Sftpa1,
Sftpb, Sftpc, and Sftpd (also known as SP-A, SP-B, SP-
C, and SP-D, respectively). According to our microarray
results, the expression of the four surfactant protein
genes increases over time in both male and female
lungs, but does not show any significant sexual differ-
ence. Compared to male lungs, Sftpa1 expression was
augmented in flutamide-treated males at GD17, while
Sftpc mRNA levels were higher in males than in fluta-
mide-treated males at GD18. Thus, our results cannot
totally exclude the participation of androgens in the
control of expression of these genes.
Some factors involved in lung morphogenesis are also
involved in surfactant synthesis regulation. Kruppel-like
factor 5 (Klf5) gene is involved in lamellar body forma-
tion, in the stability of DPPC and Sftpb levels in late
gestation in mouse, and in lung maturation during the
saccular stage of development [48]. Klf5 is regulated by
androgens since its expression is higher in flutamide-
treated male than in male and female at GD17. Klf5
influences paracrine signalling between lung epithelium
and mesenchyme, including TGF-b pathway. TGF-b was
shown to inhibit expression of Sftpa1, Sftpb, and Sftpc
surfactant proteins [49]. TGF-b is produced as a latent
complex, which must be activated by cleavage [50]. The
latent transforming growth factor-b-binding protein
(Ltbp1) has been shown to facilitate secretion of latent
TGF-b [51] and to target latent TGF-b to the extracellu-
lar matrix for storage [52]. Ltbp1 protein cleavage may
provide a mechanism for release of the latent TGF-b
from ECM [53]. The fact that Ltbp1 is more highly
expressed in males suggests that TGF-b pathway activa-
tion could be more pronounced in males compared to
females. As alleged by others, TGF-b-induced inhibition
of endodermal morphogenesis is associated with inhibi-
tion of cell proliferation, which is in large part due to
increased expression of Pten [54]. Control males
expressed Pten at higher levels than females and fluta-
mide-treated males at GD17. However, at GD18, fluta-
mide caused an increase in Pten expression in males,
suggesting a switch in the Pten expression peak from
male to female at GD18. Pten binds the scaffolding pro-
tein Magi-1 [55] which shows a sexual difference with a
male prevalence at GD17. Magi-1/2/3 proteins are
implicated in recruiting Pten to intercellular junctions
[56,57] and may play a crucial role in organizing thy-
moma viral proto-oncogene (AKT) and phosphatidylino-
sitol 3-kinase (PI3K) signalling complexes that control
cell growth, differentiation, and dissemination [55,58].
Several members of insulin-like growth factor (IGF)
family show flutamide-responsive expression. Indeed,
genes coding for Igf binding proteins Igfbp2 and Igfbp5,
as well as Igf1 and Igf receptor 2 (Igfr2) are more highly
expressed in males when compared to flutamide-treated
males. Among them, only the Igfr2 gene exhibits a sex-
ual difference, being more highly expressed in males
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regulation is prostaglangin E2 (Ptges2), which increases
surfactant secretion in rat [59]. In our study, Ptges2 is
more highly expressed in females at GD17, suggesting
that surfactant secretion could be up-regulated as a con-
sequence of Ptges2 expression.
Conclusion
While early lung development is characterized by cell
proliferation, late lung development is predominantly
governed by cell differentiation processes during which
proliferation is markedly reduced. The fact that male-
GD17 lungs showed increased expression of some prolif-
erative signals, like Fgf10, compared to female lungs put
forward the thesis that male lungs are not yet fully
engaged in the differentiation processes at GD17, but
Tgfbr3 receptor expression suggests a tight control of
cell proliferation. Even if TGF-b is a negative regulator of
airway branching morphogenesis in early lung develop-
ment, its signalling is active in several tissue types in the
lung during normal late development [60]. We also have
shown that four genes related to the Igf pathway are
more highly expressed in male lungs at GD17. This path-
way is involved in the mechanism of lung maturation
leading to surfactant synthesis. Thus, male lungs at GD17
appear to continue their growth and to start their
maturation at the same time in preparation to birth. The
male-increased expression of components from two
opposite signals, one promoting cell proliferation and
another one promoting cell differentiation, suggests a
progressive evolution from the proliferative to differentia-
tion states in some cell types within male lungs at GD17.
Furthermore, many genes involved in lipid processing
have been shown to be expressed with sexual dimorph-
i s m .S o m eg e n e si n v o l v e di nt h i sp r o c e s sh a v eas e x u a l
difference at GD17 or GD18, and some show flutamide-
sensitive modulation. Even though it is difficult to con-
firm that the phospholipids synthesis is delayed for one
sex, it is well known that the male disadvantage in lung
maturation is mediated by androgens and that these
steroids lead to a reduction in choline incorporation
into DPPC in vitro [7,61], which is in line with our
results showing that the enzyme responsible for DPPC
production is up-regulated by antiandrogen, thus con-
firming a negative effect of androgens on this process. It
should be mentioned that the sex difference in surfac-
tant lipid levels may also be attributed in part to pul-
monary expression of some apolipoproteins [62].
Generally, the male lung seems more “transcriptionally
active” than the female lung at GD17. Indeed, the major-
ity of genes differentially expressed between sexes are
more highly expressed in males. This transcriptional
activity difference suggests that some processes are
delayed in male lungs compared to females. Accordingly,
there is an obvious decrease in transcriptional activity in
male lungs between GD17 and GD18 while, during the
same period, the number of genes showing a higher
expression level in female lungs remain stable.
Taken together, our results are compatible with a
delay in expression of pathways related to late develop-
ment for one sex, with female lungs already more
advanced in their maturation process, and male lungs
showing an important transcriptional activity for path-
ways related to proliferation. By identifying several
genes that are modulated according to sex and/or by
antiandrogen in male fetal lungs, this study provides a
significant number of candidate genes under the control
of androgens that are likely to be involved in the delay
in lung maturation observed in males. Further investiga-
tions of these candidates will be helpful in the under-
standing of this sexual dimorphism and have the
potential to give valuable insights relevant to the pre-
vention and treatment of short- and long-term conse-
quences resulting from a wide range of pathologies
associated with lung immaturity, such as RDS and BPD.
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